Arthur T. Porter, MD, MBA

Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not

Over the last 10 years, we have learned more about not only the natural history of untreated locally advanced prostate cancer but also the ways in which we can effectively modify radiation therapy to treat this disease. There are now sufficient data to suggest that patients with prostate cancer that is considered locally advanced (stages T2b to T4) have a propensity for the development of lymph node metastasis and occult distant spread. In these patients, there also is a recognized difficulty in controlling the disease locally with radiation, due to the bulk of tumor present and the surrounding dose-limiting, late-reacting normal tissues.

The American Cancer Society estimates that 383,000 The American Cancer Society estimates that 383,000 Americans willbe diagnosed with prostatic or breast cancer in 1994.[1] Manyof these individuals will develop painful bony metastases. Asclinicians, it is imperative that we seek out the most

Attendees at this conference, held during the annual meetingof the American Society of Therapeutic Radiology and Oncology,were presented with nine case reports and asked how they wouldmanage each patient. The panel

The utility of strontium-89 (Sr-89) in thetreatment of advanced metastatic prostate cancer has been examinedin numerous clinical trials. Early phase II efficacy studies demonstratedthat the majority of Sr-89-treated patients